Repurposing Drugs to Treat Cardiovascular Disease in the Era of Precision Medicine

Overview

Journal Nat Rev Cardiol

Specialty Cardiology & Vascular Diseases

Date 2022 May 23

PMID 35606425

Authors

Mena Abdelsayed

Eric J Kort

Stefan Jovinge

Mark Mercola

Affiliations

Soon will be listed here.

Abstract

Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The concept is appealing because of potentially lower development costs and shorter timelines than are needed to produce a new drug. To date, drug repurposing for cardiovascular indications has been opportunistic and driven by knowledge of disease mechanisms or serendipitous observation rather than by systematic endeavours to match an existing drug to a new indication. Innovations in two areas of personalized medicine - computational approaches to associate drug effects with disease signatures and predictive model systems to screen drugs for disease-modifying activities - support efforts that together create an efficient pipeline to systematically repurpose drugs to treat cardiovascular disease. Furthermore, new experimental strategies that guide the medicinal chemistry re-engineering of drugs could improve repurposing efforts by tailoring a medicine to its new indication. In this Review, we summarize the historical approach to repurposing and discuss the technological advances that have created a new landscape of opportunities.

Citing Articles

Drug Repurposing and Nanotechnology for Topical Skin Cancer Treatment: Redirecting toward Targeted and Synergistic Antitumor Effects.

Martins M, Veiga F, Paiva-Santos A, Pires P ACS Pharmacol Transl Sci. 2025; 8(2):308-338.

PMID: 39974652 PMC: 11833728. DOI: 10.1021/acsptsci.4c00679.

Gradient coating of extracellular matrix derived from endothelial cells on aligned PCL nanofibers for rapid endothelialization.

Zhou Z, Lin Y, Liu N, Zhang Y, Li B, Wang Y Front Bioeng Biotechnol. 2025; 12():1527046.

PMID: 39845372 PMC: 11751034. DOI: 10.3389/fbioe.2024.1527046.

H1 Antihistamines-Promising Candidates for Repurposing in the Context of the Development of New Therapeutic Approaches to Cancer Treatment.

Trybus E, Trybus W Cancers (Basel). 2025; 16(24.

PMID: 39766152 PMC: 11674717. DOI: 10.3390/cancers16244253.

Conductive Microfibers Improve Stem Cell-Derived Cardiac Spheroid Maturation.

Gonzalez G, Molley T, LaMontagne E, Balayan A, Holman A, Engler A J Biomed Mater Res A. 2024; 113(1):e37856.

PMID: 39719888 PMC: 11703634. DOI: 10.1002/jbm.a.37856.

Harnessing the power of structure-based design: A new lease on life for cardiovascular drug development with apelin receptor modulators.

Zhang J, Dong E, Zhang Y Clin Transl Med. 2024; 14(12):e70116.

PMID: 39648165 PMC: 11625507. DOI: 10.1002/ctm2.70116.

References

Grover M, Ballouz S, Mohanasundaram K, George R, Goscinski A, Crowley T . Novel therapeutics for coronary artery disease from genome-wide association study data. BMC Med Genomics. 2015; 8 Suppl 2:S1. PMC: 4460746. DOI: 10.1186/1755-8794-8-S2-S1. View

Umbarkar P, Singh A, Tousif S, Zhang Q, Sethu P, Lal H . Repurposing Nintedanib for pathological cardiac remodeling and dysfunction. Pharmacol Res. 2021; 169:105605. PMC: 8217286. DOI: 10.1016/j.phrs.2021.105605. View

Yu H, Zhong X, Gao P, Shi J, Wu Z, Guo Z . The Potential Effect of Metformin on Cancer: An Umbrella Review. Front Endocrinol (Lausanne). 2019; 10:617. PMC: 6760464. DOI: 10.3389/fendo.2019.00617. View

McGowan N, Nichols M, Bilderbeck A, Goodwin G, Saunders K . Blood pressure in bipolar disorder: evidence of elevated pulse pressure and associations between mean pressure and mood instability. Int J Bipolar Disord. 2021; 9(1):5. PMC: 7847910. DOI: 10.1186/s40345-020-00209-x. View

Broch K, Anstensrud A, Woxholt S, Sharma K, Tollefsen I, Bendz B . Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2021; 77(15):1845-1855. DOI: 10.1016/j.jacc.2021.02.049. View

Del Alamo J, Lemons D, Serrano R, Savchenko A, Cerignoli F, Bodmer R . High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. Biochim Biophys Acta. 2016; 1863(7 Pt B):1717-27. PMC: 4885786. DOI: 10.1016/j.bbamcr.2016.03.003. View

Porto R, Mengarda A, Cajas R, Salvadori M, Teixeira F, Arcanjo D . Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite . Pharmaceuticals (Basel). 2021; 14(7). PMC: 8308662. DOI: 10.3390/ph14070686. View

Buch M, Smolen J, Betteridge N, Breedveld F, Burmester G, Dorner T . Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011; 70(6):909-20. PMC: 3086093. DOI: 10.1136/ard.2010.144998. View

Leary P, Tedford R, Bluemke D, Bristow M, Heckbert S, Kawut S . Histamine H2 Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk: The MESA Study. J Am Coll Cardiol. 2016; 67(13):1544-1552. PMC: 4860615. DOI: 10.1016/j.jacc.2016.01.045. View

10.

Keiser M, Setola V, Irwin J, Laggner C, Abbas A, Hufeisen S . Predicting new molecular targets for known drugs. Nature. 2009; 462(7270):175-81. PMC: 2784146. DOI: 10.1038/nature08506. View

11.

Inoue H, Nagata N, Kurokawa H, Yamanaka S . iPS cells: a game changer for future medicine. EMBO J. 2014; 33(5):409-17. PMC: 3989624. DOI: 10.1002/embj.201387098. View

12.

Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295(23):2727-41. DOI: 10.1001/jama.295.23.joc60074. View

13.

Guo C, Ma W, Drew D, Cao Y, Nguyen L, Joshi A . Aspirin Use and Risk of Colorectal Cancer Among Older Adults. JAMA Oncol. 2021; 7(3):428-435. PMC: 7821085. DOI: 10.1001/jamaoncol.2020.7338. View

14.

Andersson D, Trolle Lagerros Y, Grotta A, Bellocco R, Lehtihet M, Holzmann M . Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017; 103(16):1264-1270. PMC: 5537549. DOI: 10.1136/heartjnl-2016-310746. View

15.

Brown J, Chan D, Shank J, Griffith K, Fan H, Szulawski R . Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight. 2020; 5(11). PMC: 7308054. DOI: 10.1172/jci.insight.133247. View

16.

Zhang J, Cai W, Zhang Z, Wang P, Lin X, Feng J . Cardioprotective effect of histamine H2 antagonists in congestive heart failure: A systematic review and meta-analysis. Medicine (Baltimore). 2018; 97(15):e0409. PMC: 5908598. DOI: 10.1097/MD.0000000000010409. View

17.

Schuhmacher A, Gatto A, Hinder M, Kuss M, Gassmann O . The upside of being a digital pharma player. Drug Discov Today. 2020; 25(9):1569-1574. DOI: 10.1016/j.drudis.2020.06.002. View

18.

Gelosa P, Castiglioni L, Camera M, Sironi L . Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?. Biochem Pharmacol. 2020; 177:113895. DOI: 10.1016/j.bcp.2020.113895. View

19.

Weeber M, Vos R, Klein H, de Jong-van den Berg L, Aronson A, Molema G . Generating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide. J Am Med Inform Assoc. 2003; 10(3):252-9. PMC: 342048. DOI: 10.1197/jamia.M1158. View

20.

Pott A, Rottbauer W, Just S . Streamlining drug discovery assays for cardiovascular disease using zebrafish. Expert Opin Drug Discov. 2019; 15(1):27-37. DOI: 10.1080/17460441.2020.1671351. View